Crescent Biopharma posts Q1 2026 results with $189m cash runway
Crescent Biopharma (Nasdaq: CBIO) has reported first-quarter 2026 financial results, recording a net loss of $23.3 million against $1.0 million in licence revenue — the latter representing the first recognition of a $20 million upfront payment from Kelun-Biotech under a collaboration agreement for its lead asset, CR-001. The Waltham, Massachusetts company held $189.2 million in cash as of 31 March 2026, which management says will fund operations into 2028.
Research and development expenditure rose to $17.9 million in the quarter, up from $10.6 million in the same period of 2025, reflecting accelerated spending on CR-001 and CR-002. General and administrative costs also increased, from $3.6 million to $7.9 million, largely attributed to the company's relatively recent listing and associated public-company infrastructure costs.
Pipeline progress
CR-001, a tetravalent bispecific antibody designed to block both PD-1 and VEGF simultaneously, remains the centrepiece of Crescent's clinical strategy. Enrolment is ongoing in ASCEND, a global Phase 1/2 open-label study evaluating the candidate across multiple solid tumour types — including non-small cell lung cancer, gastrointestinal and gynaecological cancers — in both treatment-naïve and previously treated patients. Proof-of-concept data, covering safety, pharmacokinetics, pharmacodynamics and early antitumour activity, are anticipated in Q1 2027, with combination chemotherapy data following in mid-2027.
A trial-in-progress abstract for ASCEND has been accepted for poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago (29 May–2 June), providing the company with its first meaningful investor-facing data forum of the year.
Two further trials are expected to initiate in the second half of 2026: a Phase 1/2 combination study pairing CR-001 with a Kelun-Biotech ADC in China, and the first-in-human trial of CR-002, a topoisomerase inhibitor ADC targeting PD-L1, pending an IND submission to the FDA expected around mid-year. A third asset, CR-003 — an ITGB6-targeted ADC being run by Kelun-Biotech in China — is already in Phase 1/2, with proof-of-concept data also expected in Q1 2027.
Chief executive Joshua Brumm said the ASCEND study design was constructed to "quickly generate comprehensive data" for CR-001 as both a monotherapy and in combination with standard-of-care chemotherapy, and that the company was working alongside Kelun-Biotech to produce ADC combination data in parallel.
Market context
The PD-1 x VEGF bispecific antibody class has attracted considerable attention since the clinical success of ivonescimab, a Chinese-developed asset that demonstrated improved progression-free survival over pembrolizumab monotherapy in NSCLC in data presented in 2024. That readout effectively validated the mechanism and intensified competitive interest in the class, with several programmes now in development globally. Crescent is positioning CR-001 as a "potentially best-in-class" candidate — a claim that will need corroboration from the Q1 2027 ASCEND readout before the market assigns it meaningful differentiation.
The ADC landscape is similarly crowded, with PD-L1-targeting ADCs and integrin-targeted conjugates both under active development by larger players. Crescent's combination strategy — running CR-001 alongside both CR-002 and CR-003 — reflects an emerging thesis that bispecific-plus-ADC combinations may outperform either modality alone, though clinical proof remains limited across the sector. Investors will be watching the 2027 data readout windows closely to assess whether Crescent's multi-modal approach translates into differentiated efficacy signals.